RNA methylation has received a new burst in interest as researchers rely on a series of pioneering EpiGentek kits to unravel its function.
Farmingdale, NY (PRWEB)
March 27, 2017
EpiGentek, a Farmingdale, NY-based biotech firm specializing in epigenetic research products enables researchers to pursue the recent RNA methylation “gold rush” with their established portfolio of optimized assay kits that measure RNA methylation. In light of the newfound characteristics of N6-methyladenosine, or m6A, RNA methylation has received a new burst in interest as researchers rely on a series of pioneering EpiGentek kits to unravel its function.
This modification was discovered years ago, but was only recently found to be a dynamic mark in RNA with a corresponding eraser enzyme and potential regulatory roles. M6A is the most abundant messenger RNA (mRNA) modification, termed the “fifth RNA base”, and is also present in transfer RNA (tRNA), ribosomal RNA (rRNA), small nuclear RNA (snRNA), and long non-coding RNA (lncRNA). Interestingly, it accounts for more than 80% of all RNA methylation.
N6-Methyladenosine has been shown to influence splicing, nuclear export, translation ability and stability, and RNA transcription. Measuring m6A is becoming increasingly important because the reversible chemical modification may serve as a novel epigenetic marker and improve our understanding of diseases.
EpiGentek debuted the very first commercially available kit for rapidly quantifying m6A RNA. Ideal for researchers aiming to quantify N6-methyladenosine, EpiGentek’s EpiQuik m6A RNA Methylation Quantification Kit performs…